TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05011916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KDR2-2 suspension eye drops
Description: All patients were instructed to instill one drop four times per day in the study eye for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KDR2-2 suspension eye drops
Description: All patients were instructed to instill one drop four times per day in the study eye for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KDR2-2 suspension eye drops
Description: All patients were instructed to instill one drop four times per day in the study eye for 6 weeks.
Study: NCT05315830

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2 Tumor Vaccine
Description: B-cell epitope vaccine HER2 Tumor Vaccine 0.6 μg，Intramuscular injection on D1, D14 and D28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2 Tumor Vaccine+ Standard of Care chemotherapy
Description: B-cell epitope vaccine HER2 Tumor Vaccine 0.6 μg，Intramuscular injection on D1, D14 and D28 Standard of Care Chemotherapy cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle) or other standard of care chemotherapy
Study: NCT06255093

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community-based recreation program referral
Description: Provide referral to local Parks and Recreation for programs of interest and participation. Participants will have the option to join a program (up to 4months) and have access to additional resources via study webpage to identify support services.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pre-surveys only
Description: Receive online wellness education and anxiety treatment options information
Study: NCT06105541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Neurostimulation
Description: Transcutaneous Auricular Neurostimulation (tAN) is a wearable, electrical stimulation device that delivers electricity to specific parts of the human ear.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Neurostimulation
Description: Transcutaneous Auricular Neurostimulation (tAN) is a wearable, electrical stimulation device that delivers electricity to specific parts of the human ear.
Study: NCT04360083

Intervention type: OTHER
Intervention: Collected data from Rhône RéPPOP database
Description: BMI Z-scores at the start and the end of RéPPOP care programs.

Intervention type: OTHER
Intervention: telephonic questionnaire
Description: Collected data though the telephonic questionnaire : current declared BMI Z-score.
Study: NCT05132530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Description: yoga practice will be done two days a week for 10 weeks.
Study: NCT05801900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac group
Description: 30 min preoperatively then every 8 hours postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen group
Description: 30 min preoperatively then every 8 hours postoperatively
Study: NCT05124821

Intervention type: DEVICE
Intervention: Central venous catheter intended to be used for children during routine clinical practice
Description: Device will applied according to instruction for use (IFU) and respective indication during routine clinical practice.
Study: NCT05995405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-104
Description: Nimodipine IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimotop 30 MG Oral Capsule
Description: Oral nimodipine capsules
Study: NCT05497232

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simultaneous pancreas-kidney transplantation
Description: Renal transplants were performed to the right external iliac artery and vein, and the ureter was anastomosed to the recipient ureter by using end-to-end anastomoses techniques. All the renal allografts were placed into retroperitoneum.~Enteric drainage of exocrine secretions was performed on all pancreas transplants, systemic venous outflow (postcava), and arterial reconstruction with y graft (iliac artery). Lastly in all cases of renal transplant, the artery was anastomosed in all cases. The pancreas was placed intra-abdominally in all cases.
Study: NCT04189133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutropin alfa
Description: daily increasing dosages of lutropin alfa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: human chorionic gonadotropin increasing administration
Study: NCT05150782

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin/Boswellia Serrata/Ascorbic acid mixture
Description: The daily intake of 2x10 drops of a mixture of micellized curcumin (2%), boswellia serrata (1.5%) and ascorbic acid (6%).
Study: NCT05559424

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: OCT
Description: OCT will be used to assess results after intervention

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: OCT
Description: OCT will be used to assess results after intervention
Study: NCT05959161

Intervention type: PROCEDURE
Intervention: DBS
Description: We observed the prognostic changes of patients after DBS surgery

Intervention type: PROCEDURE
Intervention: DBS
Description: We observed the prognostic changes of patients after DBS surgery
Study: NCT06076824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: The intervention group will recieve 7 mg/kg/day (or a maximum of 500 mg/day) of intravenous Methylprednisolone an hour before TAVR followed by 15 mg / 12h of Prednisone during 5 days after the intervention (starting 24h after the administration of Methylprednisolone).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study: NCT05459025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aromatherapy yoga
Description: The research assistant diluted the Lavandula angustifolia essential oil with distilled water (1:75) 10 min before the yoga session started. The solution was then atomized by three aroma diffusers, placed in the front, middle, and back of the classroom. The distance from each participant was less than 10 m to ensure that the aroma was absorbed com-pletely. The yoga course for the aromatherapy yoga group was the same as that of the yoga only group. The yoga group only took a yoga course, without aromatherapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: The design of the yoga lessons was based on a past study and a professional yoga instruction book. Yoga lessons were led by certified yoga tutors.
Study: NCT04849533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: belatacept with everolimus is experimental regimen and it is compared to the labeled regimen of belatacept with mycophenolate with steroids for prevention of rejection in renal transplant recipients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belatacept
Description: belatacept with everolimus is experimental regimen and it is compared to the labeled regimen of belatacept with mycophenolate with steroids for prevention of rejection in renal transplant recipients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: belatacept with everolimus is experimental regimen and it is compared to the labeled regimen of belatacept with mycophenolate with steroids for prevention of rejection in renal transplant recipients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: belatacept with mycophenolate is approved regimen for prevention of rejection
Study: NCT06455332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optic nerve MRI sequence
Description: Systematic optic nerve MRI sequence during the CIS diagnosis work-up. This sequence is not done systematically and not recommended for now (except in case of acute ON). The interventional nature of the study remains minimal
Study: NCT05169814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micro/nanobubble (MNB) - Irrigation
Description: An MNB solution will be used as an irrigation solution to improve wound oxygenation in ischemic tissue (e.g. ischemic surgical tissue, traumatic wounds, and failing replants). The MNB solution will be used in wet-to-dry wound care dressings with daily scheduled dressing changes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline - Irrigation
Description: A normal saline solution will be used as an irrigation solution to improve wound oxygenation in ischemic tissue (e.g. ischemic surgical tissue, traumatic wounds, and failing replants). The normal saline solution will be used in wet-to-dry wound care dressings with daily scheduled dressing changes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micro/nanobubble (MNB) - Negative Pressure Wound Therapy with Instillation (NPWTi)
Description: NPWTi with MNB will be applied to the wound with 20-minute instillation periods every 3 hours (standard instillation settings) with dressing changes every 3-5 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline - Negative Pressure Wound Therapy with Instillation (NPWTi)
Description: NPWTi with normal saline will be applied to the wound with 20-minute instillation periods every 3 hours (standard instillation settings) with dressing changes every 3-5 days.
Study: NCT06646653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alma System
Description: Subjects diagnosed with postpartum hemorrhage will receive the Alma System. This system comprises a soft silicone cylindrical device placed within the uterus. Gentle suction is applied, prompting the uterus to contract and reduce in size. This contraction compresses the blood vessels, halting the bleeding.
Study: NCT05680285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode lazer
Description: diode laser was applied during the pulpotomy procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level diode laser
Description: Low-dose diode laser was applied during the pulpotomy procedure
Study: NCT05139498

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative management for placenta accreta spectrum (PAS)
Description: Subjects who are randomized to to conservative management will undergo a cesarean delivery followed by a period of close observation in the operating room for 30-45 minutes to be sure there is no excessive bleeding or risk to keep the placenta inside

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean hysterectomy for placenta accreta spectrum (PAS)
Description: Subjects who are randomized to cesarean hysterectomy will undergo a cesarean delivery followed immediately by hysterectomy to remove the placenta and uterus together
Study: NCT04849533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: belatacept with chronic steroids is approved regimen for prevention of rejection
Study: NCT06238297

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRSA nasal swab based de-escalation
Description: Patients included into the intervention arm will undergo a nasal swab for MRSA and empirical anti-MRSA therapy will be discontinued f the nasal swab result is negative.
Study: NCT05910697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyProstateScore 2.0 Results
Description: Being shown the results of a diagnostic test for the likelihood of finding clinically significant cancer from a prostate biopsy and how it changes clinical practice.
Study: NCT04666376

Intervention type: OTHER
Group type: OTHER
Intervention: evaluation of the effectiveness of vitrification technique on ovarian tissue quality
Description: there are 3 types of experiments in each group, including Follicle survival evaluation by Neutral red staining, Histological evaluation by Hematoxylin and Eosin staining, 2.4. Evaluation GDF-9 and Caspase-3 gene expression by real-time PCR.
Study: NCT04849533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit antithymocyte globulin
Description: rabbit antithymocyte globulin induction for prevention of rejection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabbit antithymocyte globulin
Description: rabbit antithymocyte globulin induction for prevention of rejection
Study: NCT05304494

Intervention type: OTHER
Intervention: Biomarker tests for participant profiling
Description: Combination of digital and physical tests to objectify measures relevant for breathlessness

Intervention type: OTHER
Intervention: Biomarker tests for participant profiling
Description: Combination of digital and physical tests to objectify measures relevant for breathlessness

Intervention type: OTHER
Intervention: Biomarker tests for participant profiling
Description: Combination of digital and physical tests to objectify measures relevant for breathlessness
Study: NCT04887701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-hormonal vaginal device therapy
Description: Experimental Active Therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vaginal device therapy
Description: Sham Comparator
Study: NCT01308047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: single dose of 15mg by a slow injection rate of 1 ml/s

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: single dose of 15mg by a slow injection rate of 1 ml/s
Study: NCT05027880

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based single-session growth mindset intervention for adolescent anxiety
Description: This proposed study uses a four-arm, parallel group, cluster randomized controlled trial design to evaluate the efficacy of SIGMA compared to a web-based growth mindset SSI (SSI-GP) and an active web-based control programme. The concurrent parallel group structure assures that the different groups take part in their respective intervention at the same time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based single-session growth mindset intervention for adolescent anxiety
Description: This proposed study uses a four-arm, parallel group, cluster randomized controlled trial design to evaluate the efficacy of SIGMA compared to a web-based growth mindset SSI (SSI-GP) and an active web-based control programme. The concurrent parallel group structure assures that the different groups take part in their respective intervention at the same time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based single-session growth mindset intervention for adolescent anxiety
Description: This proposed study uses a four-arm, parallel group, cluster randomized controlled trial design to evaluate the efficacy of SIGMA compared to a web-based growth mindset SSI (SSI-GP) and an active web-based control programme. The concurrent parallel group structure assures that the different groups take part in their respective intervention at the same time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based single-session growth mindset intervention for adolescent anxiety
Description: This proposed study uses a four-arm, parallel group, cluster randomized controlled trial design to evaluate the efficacy of SIGMA compared to a web-based growth mindset SSI (SSI-GP) and an active web-based control programme. The concurrent parallel group structure assures that the different groups take part in their respective intervention at the same time.
Study: NCT05871671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: A 16-week PR programme shall be delivered twice weekly to the active group. This shall be followed by a 36-week maintenance home exercise programme which shall be monitored every 4 weeks via a phone call from the researcher herself for 36 weeks. The subjects shall self-document their adherence to the home exercise programme on a diary which shall be returned to the researcher at week 52.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group shall not receive the 16-week PR programme and the following 36-week maintenance home exercise programme until completion of the study.
Study: NCT05131789

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dementia case management information system
Description: The investigators will develop an information system based on the data collected in our previous research, the content and method of dementia case management which will be established by the Delphi method, and then the dementia case management information system will be constructed accordingly.
Study: NCT06062953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 3-9 mg flexible dosing before bed time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: 50-150 mg flexible dosing before bed time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-3 capsules flexible dosing before bed time
Study: NCT06048575

Intervention type: PROCEDURE
Intervention: Cholecystectomy
Description: Early or late surgery, ambulatory, emergency, or differed.

Intervention type: PROCEDURE
Intervention: Cholecystectomy
Description: Early or late surgery, ambulatory, emergency, or differed.
Study: NCT05753319

Intervention type: OTHER
Intervention: Physiotherapy in the emergency department after a fall
Description: Realization of a physiotherapy assessment.
Study: NCT06404073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Pacing
Description: Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication.
Study: NCT04826419

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ozone therapy
Description: The treatment session of oxygen-ozone was 80 mg/mL ozone (total volume: 60-100 mL) in a special bag using the ozone generator device (Humazon Promedic, German) five times a week for the first week.The treatment session of oxygen-ozone was 40 mg/mL ozone (total volume: 60-100 mL) in a special bag using the ozone generator device (Humazon Promedic, German) twice a week after first week.
Study: NCT06048575

Intervention type: PROCEDURE
Intervention: Cholecystectomy
Description: Early or late surgery, ambulatory, emergency, or differed.
Study: NCT05132088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide 50 mg
Description: Participants will have semaglutide for 68 weeks and will have 1 tablet every morning.~Dose gradually increased to 50 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (semaglutide)
Description: Participants will have placebo tablets for 68 weeks and will have 1 tablet every morning.
Study: NCT04633213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9036 0.25% Ophthalmic Solution
Description: Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ophthalmic Solution
Study: NCT05166720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIDCAP care
Description: NIDCAP care was performed according to the best evidence of NIDCAP
Study: NCT05425680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core muscle training
Description: Combining virtual reality technology and waist wearable sensors, training the pelvis and lumbar spine movements as the main training goal, it is estimated that two 1-hour training sessions per week, a total of 6 weeks of training, to improve the core muscle of patients with lumbar degenerative diseases muscle strength.
Study: NCT04314570

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saphenous Nerve Block with Ropivacaine Treatment
Description: Regional Anesthesia nerve blocks have become standard practice for several orthopedic surgeries for post-operative pain management, however concerns for compartment syndrome have prevented nerve blocks to become common practice for tibial plateau open reduction internal fixation pain management. Interestingly, saphenous nerve blocks do not cover the sciatic nerve, allowing for pain management while reducing concerns that it may possibly mask compartment syndrome. Patients will receive ropivacaine through the catheter from the start of the nerve block.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saphenous Nerve Block with Saline Control
Description: Regional Anesthesia nerve blocks have become standard practice for several orthopedic surgeries for post-operative pain management, however concerns for compartment syndrome have prevented nerve blocks to become common practice for tibial plateau open reduction internal fixation pain management. Interestingly, saphenous nerve blocks do not cover the sciatic nerve, allowing for pain management while reducing concerns that it may possibly mask compartment syndrome. Patients will receive a loading dose of Normal Saline through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
Study: NCT06263517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clodronate
Description: For Arm 1, patients will be treated with intra articular clodronate 2 mg/2 ml from Baseline to Week 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clodronate
Description: For Arm 2, patients will be treated with intra articular clodronate 5 mg/2 ml from Baseline to Week 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clodronate
Description: For Arm 3, patients will be treated with intra articular clodronate 10 mg/2 ml from Baseline to Week 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For Arm 4, patients will be treated with Placebo 2 ml from Baseline to Week 3
Study: NCT06209047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bronchoscopic airway clearance followed by local instillation of gentamicin and dexamethasone
Description: bronchoscopic airway clearance followed by local instillation of gentamicin and dexamethasone
Study: NCT05691166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training
Description: Supervised high-intensity progressive resistance training twice per week for 12 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General practitioner care
Description: Referred to general practitioner (GP) for further follow-up. The GPs will be informed about participants sarcopenia status with results from assessments of muscle strength, muscle mass, and physical performance. The management of the sarcopenia is at the GPs own discretion.